Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Market: Market:

Biocept Inc (BIOC)

Biocept Inc (BIOC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020 PR Newswire - PRF - Wed May 20, 7:05AM CDT
CMTX - Wed May 20, 7:05AM CDT

, /PRNewswire/ -- . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients...

BIOC : 0.4980 (-1.39%)
Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories PR Newswire - PRF - Thu May 14, 7:05AM CDT
CMTX - Thu May 14, 7:05AM CDT

, /PRNewswire/ -- . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients...

BIOC : 0.4980 (-1.39%)
Biocept Reports First Quarter 2020 Financial Results PR Newswire - PRF - Wed May 13, 3:05PM CDT
CMTX - Wed May 13, 3:05PM CDT

, /PRNewswire/ -- (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Liquid Biopsy Industry Outlook 2020-2030 by Product, End-user, Clinical Application, Region, Country PR Newswire - PRF - Tue May 5, 7:45AM CDT
CMTX - Tue May 5, 7:45AM CDT

, /PRNewswire/ -- The report has been added to offering.

BIOC : 0.4980 (-1.39%)
MYGN : 14.27 (-3.16%)
QGEN : 43.26 (+0.63%)
Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020 PR Newswire - Wed Apr 29, 7:05AM CDT
CMTX - Wed Apr 29, 7:05AM CDT

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Biocept Announces CE-IVD Mark and Availability of its Target Selector(TM) EGFR Molecular Assay Kit in Europe PR Newswire - Tue Apr 28, 7:05AM CDT
CMTX - Tue Apr 28, 7:05AM CDT

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector(TM) Technology Validated for Use in Both Tissue and Blood Samples PR Newswire - Mon Apr 20, 7:05AM CDT
CMTX - Mon Apr 20, 7:05AM CDT

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market PR Newswire - Tue Apr 14, 8:00AM CDT
CMTX - Tue Apr 14, 8:00AM CDT

Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes...

BIOC : 0.4980 (-1.39%)
Biocept to Begin COVID-19 Testing PR Newswire - Thu Apr 9, 6:18PM CDT
CMTX - Thu Apr 9, 6:18PM CDT

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Brazil Patent Granted for Biocept's Target Selector(TM) Oncogene Mutation Enrichment and Detection Platform PR Newswire - Thu Apr 9, 7:05AM CDT
CMTX - Thu Apr 9, 7:05AM CDT

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform PR Newswire - Thu Apr 2, 7:05AM CDT
CMTX - Thu Apr 2, 7:05AM CDT

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association PR Newswire - Thu Mar 26, 7:05AM CDT
CMTX - Thu Mar 26, 7:05AM CDT

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Biocept Reports 2019 Fourth Quarter and Full Year Financial Results PR Newswire - Wed Mar 25, 3:05PM CDT
CMTX - Wed Mar 25, 3:05PM CDT

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports...

BIOC : 0.4980 (-1.39%)
Biocept, Inc. to Host Earnings Call ACCESSWIRE - Wed Mar 25, 1:31PM CDT
CMTX - Wed Mar 25, 1:31PM CDT

NEW YORK, NY / ACCESSWIRE / March 25, 2020 / Biocept, Inc. (NASDAQ:BIOC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 25, 2020 at 4:30 PM Eastern...

BIOC : 0.4980 (-1.39%)
Biocept, Inc. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network ACCESSWIRE - Wed Mar 18, 7:30AM CDT
CMTX - Wed Mar 18, 7:30AM CDT

LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 / , The Official MicroCap News Source™, today published an SNNLive Video Interview with Mike Nall, CEO of Biocept, Inc. (NASDAQ:BIOC), a leading commercial...

BIOC : 0.4980 (-1.39%)
Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020 PR Newswire - Wed Mar 18, 7:05AM CDT
CMTX - Wed Mar 18, 7:05AM CDT

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector(TM) qPCR Assay to Identify Cancer-Associated Mutations PR Newswire - Mon Mar 9, 7:05AM CDT
CMTX - Mon Mar 9, 7:05AM CDT

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market PR Newswire - Thu Mar 5, 7:30AM CST
CMTX - Thu Mar 5, 7:30AM CST

Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes...

BIOC : 0.4980 (-1.39%)
Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market PR Newswire - Mon Mar 2, 7:30AM CST
CMTX - Mon Mar 2, 7:30AM CST

Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes...

BIOC : 0.4980 (-1.39%)
Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations PR Newswire - Fri Feb 14, 7:05AM CST
CMTX - Fri Feb 14, 7:05AM CST

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Please wait...

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
Mon Dec 30, 3:58PM CST
CRUS +0.22 , SEDG +6.15 , THC +0.93 , TER +2.10 , LITE +0.93
See More
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot